Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 ...
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in ...
BP said it received final approval from the Iraqi government for the redevelopment of the giant Kirkuk oil fields, with an ...
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company committed to the development and ...
Clinical Trials Arena on MSN22h
Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosisThe trial aims to evaluate the antibody’s efficacy in treating non-active secondary progressive multiple sclerosis.
X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.
1don MSN
Government health officials detected as many as 719,000 new TB cases during a short, 100-day TB camp held last year, in ...
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...
The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback